Brief: Viracta Therapeutics Announces Preliminary Dose-Ranging Data Of Nana-Val In Advanced Epstein-Barr Virus-Positive Solid Tumors

Viracta Therapeutics

30/11/2022 23:20

Nov 30 (Reuters) - Viracta Therapeutics Inc  VIRX.O :
    * VIRACTA THERAPEUTICS ANNOUNCES PRELIMINARY DOSE-RANGING
DATA
FROM THE PHASE 1B/2 TRIAL OF NANA-VAL IN ADVANCED EPSTEIN-BARR
VIRUS-POSITIVE (EBV+) SOLID TUMORS AT THE ESMO IMMUNO-ONCOLOGY
CONGRESS
    * COMPANY ANTICIPATES INITIATING PHASE 2 RANDOMIZED
EXPANSION
PORTION OF PHASE 1B/2 TRIAL IN SECOND HALF OF 2023
    * COMPANY ANTICIPATES INITIATING PHASE 2 RANDOMIZED
EXPANSION
PORTION OF PHASE 1B/2 TRIAL IN SECOND HALF OF 2023
    * NANA-VAL WAS WELL TOLERATED WITH NO DOSE LIMITING
TOXICITIES
(DLTS) REPORTED
    * TWO OF SIX EVALUABLE PATIENTS ACHIEVED STABLE DISEASE (SD)
PER
RECIST V1.1 CRITERIA
    * PLASMA EBV DNA TITERS DECREASED OR REMAINED STABLE IN BOTH
PATIENTS ACHIEVING SD
    * PLASMA EBV DNA TITERS ROSE IN PATIENTS WITH PROGRESSIVE
DISEASE

Source text for Eikon:  ID:nGNX8XvJ7d 
Further company coverage:  VIRX.O 
 ((Reuters.Briefs@thomsonreuters.co))